Zhejiang Huahai Pharmaceutical (SHA:600521) received a drug registration certificate from China's National Medical Products Administration for its vonoprazan fumarate tablets.
The drug is indicated for reflux esophagitis. It could also be used in combination with antibiotics against Helicobacter pylori, according to an Aug. 7 disclosure on the Shanghai bourse.